

Bibliographic Information: JP 2001206856

Chloroindolephenylethylamide analogs and their prodrugs as glycogen phosphorylase inhibitors for treatment of diabetic cardiomyopathy. Treadway, Judith Lee. (Pfizer Products Inc., USA). Jpn. Kokai Tokkyo Koho (2001), 35 pp. CODEN: JKXXAF JP 2001206856 A2 20010731 Patent written in Japanese. Application: JP 2001-14036 20010123. Priority: US 2000-177770 20000124. CAN 135:132447 AN 2001:554794 CAPLUS

Patent Family Information

	Patent No.	Kind	Date	Application No.	Date
5	JP 2001206856	A2	20010731	JP 2001-14036	20010123
	NZ 509481	A	20050225	NZ 2001-509481	20010119
	CA 2331847	AA	20010724	CA 2001-2331847	20010122
15	ZA 2001000607	A	20020722	ZA 2001-607	20010122
	EP 1125580	A2	20010822	EP 2001-300575	20010123
	EP 1125580	A3	20021127		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO US 2001046958				
20	US 6867184	B2	20050315		
	Priority Application				
	US 2000-177770P	P		20000124	

Abstract

Chloroindolephenylethylamide analogs, including 5-chloro-1H-indole-2-carboxylic acid [(1S)-(R)-hydroxydimethylcarbamoylmethyl]-2-phenylethyl]amide, etc., and their prodrugs are claimed as glycogen phosphorylase inhibitors for treatment of diabetic cardiomyopathy. The title compds. can also combine with insulin, insulin analogs (biguanides), α 2-agonists, imidazolines, glitazone derivs., PPAR γ agonists, fatty acid oxidn. inhibitors, α -glucosidase inhibitors, β -agonists, phosphodiesterase inhibitors, hypolipidemics, antiobesity agents, vanadium salts, glucagon antagonists, somatostatin analogs, aldose reductase inhibitors, sorbitol dehydrogenase inhibitors, glucocorticoid receptor antagonists, and/or thyroid hormone analogs for treatment of diabetes, cardiovascular diseases, heart ischemia, congestive heart failure, hypertension, diabetic angiopathy, myocardial infarction, etc.